Company intelligence / Profile preview
CinPhloro Pharma
Cincinnati, Ohio, United Statescinphloro.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
CinPhloro Pharma is currently conducting the Phase 2 "enviva" study (NCT06153420) of CIN-103 for IBS-D. The first participant was dosed in February 2024. The study aims to enroll 450 adults with IBS-D to evaluate the safety, efficacy, and tolerability of CIN-103 over 12 weeks of treatment[1][8].
- Therapeutic areas
- Gastroenterology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on CinPhloro Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CinPhloro Pharma.